When Ben Chien, PhD, QPS Chairman, President and CEO, first started a small bioanalytical lab with just three people, he wasn’t expecting it to grow into a worldwide CRO with more than 1,150 employees.
“In the beginning, we were just happy to be serving the client well, producing high-quality data,” said Chien. But after a few years he knew the company could grow and provide integrated services to clients.
In the fourth video in our six-part 20th Anniversary series, Chien explains that providing integrated CRO services to clients is still one of his passions. But how is a small, privately held company like QPS going to compete in an industry increasingly dominated by giants? Is the CRO industry headed towards more consolidation, or will we next see an era of more specialization?
Hear Chien detail his expectations for the industry as he explains how QPS will continue its efforts to better patients’ lives by helping clients navigate the drug development pipeline from early stage through market approval.
[arve url=”https://www.youtube.com/watch?v=arFvaL8AtmQ” /]
QPS CEO Predicts Where Industry, Company are Headed: QPS 20th Anniversary Series, Part 4 from QPS Holdings
